The Clinical Impact of β-Blocker Therapy on Patients with Chronic Coronary Artery Disease after Percutaneous Coronary Intervention

Jiesuck Park, Jung Kyu Han, Jeehoon Kang, In Ho Chae, Sung Yun Lee, Young Jin Choi, Jay Young Rhew, Seung Woon Rha, Eun Seok Shin, Seong Ill Woo, Han Cheol Lee, Kook Jin Chun, Doo Il Kim, Jin Ok Jeong, Jang Whan Bae, Han Mo Yang, Kyung Woo Park, Hyun Jae Kang, Bon Kwon Koo, Hyo Soo Kim

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Background and Objectives: The outcome benefits of β-blockers in chronic coronary artery disease (CAD) have not been fully assessed. We evaluated the prognostic impact of β-blockers on patients with chronic CAD after percutaneous coronary intervention (PCI). Methods: A total of 3,075 patients with chronic CAD were included from the Grand Drug-Eluting Stent registry. We analyzed β-blocker prescriptions, including doses and types, in each patient at 3-month intervals from discharge. After propensity score matching, 1,170 pairs of patients (β-blockers vs. no β-blockers) were derived. Primary outcome was defined as a composite endpoint of all-cause death and myocardial infarction (MI). We further analyzed the outcome benefits of different doses (low-, medium-, and high-dose) and types (conventional or vasodilating) of β-blockers. Results: During a median (interquartile range) follow-up of 3.1 (3.0–3.1) years, 134 (5.7%) patients experienced primary outcome. Overall, β-blockers demonstrated no significant benefit in primary outcome (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.63–1.24), all-cause death (HR, 0.87; 95% CI, 0.60–1.25), and MI (HR, 1.25; 95% CI, 0.49–3.15). In subgroup analysis, β-blockers were associated with a lower risk of all-cause death in patients with previous MI and/ or revascularization (HR, 0.38; 95% CI, 0.14–0.99) (p for interaction=0.045). No significant associations were found for the clinical outcomes with different doses and types of β-blockers. Conclusions: Overall, β-blocker therapy was not associated with better clinical outcomes in patients with chronic CAD undergoing PCI. Limited mortality benefit of β-blockers may exist for patients with previous MI and/or revascularization.

Original languageEnglish
Article numbere50
JournalKorean Circulation Journal
Publication statusPublished - 2022 May
Externally publishedYes

Bibliographical note

Funding Information:
This study was funded by Chong Kun Dang Inc. (Seoul, Republic of Korea) (grant 0620173860). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Publisher Copyright:
© 2022 Korean Society of Circulation. All rights reserved.


  • Adrenergic beta-antagonists
  • Angina, stable
  • Percutaneous coronary intervention

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'The Clinical Impact of β-Blocker Therapy on Patients with Chronic Coronary Artery Disease after Percutaneous Coronary Intervention'. Together they form a unique fingerprint.

Cite this